Facebook
X
LinkedIn
Forward
Navigating Chronic Urticaria Care Today and Tomorrow
The symptoms and management of chronic urticaria (CU) can present significant challenges for affected patients. Although antihistamines are the first-line option for patients with CU, many do not achieve adequate symptom control. Current treatments target histamine or autoantibodies, but novel therapies, such as Bruton’s tyrosine kinase inhibitors, are being developed. To effectively manage chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), HCPs require education on the recommendations for diagnosis and management of these conditions, as well as the clinical efficacy and safety of new and emerging treatments. This on-demand session, recorded during the 2026 South Beach Symposium, will provide learners with expert-guided instruction on the recognition and diagnosis of CSU/CIndU, as well as the most up-to-date clinical data for current and emerging targeted therapies to overcome unmet treatment needs.
Target Audience
This session is designed for an audience of US-based physicians, nurses, advanced practice providers and professional staff members of medical practices specializing in dermatology.
Learning Objectives
Upon completion of the educational activity, participants should be better able to:
- Distinguish the clinical features of chronic spontaneous urticaria, chronic inducible urticaria, and similar conditions to facilitate initiation of appropriate treatment.
- Critically analyze the clinical data for current and emerging targeted therapies for chronic urticaria to overcome treatment challenges.
- Advanced Wound Care
- Multidisciplinary Care Strategies
- Best Practices and Key Takeaways
| |
Hadar Lev Tov, MD |
|
This activity is jointly provided by Global Education Group (Global) and LivDerm.
This activity is supported by an educational grant from Organogenesis, Inc.
In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and Tarsus Cardio dba LiVDerm. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.
Physician
AKH Inc., Advancing Knowledge in Healthcare designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
0.5 ANCC contact hours.
Physician Assistant
AKH Inc., Advancing Knowledge in Healthcare has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until May 15, 2026. PAs should only claim credit commensurate with the extent of their participation.
Commercial Support
This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.
Disclosure
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.
DISCLOSURES | ||
Name | Relationship | Commercial Interest |
Christopher G. Bunick, MD, PhD | Advisor | AbbVie, Almirall, Alumis, Amgen, Apogee, Arcutis, Botanix, Castle Biosciences, Connect BioPharma, Daiichi Sankyo, Dermavant, Disc Medicine, Eli Lilly, EPI Health/Novan, Galderma, Incyte, LEO Pharma, Novartis, Ortho Dermatologics, Palvella, Pfizer, Regeneron, Sanofi, South Beach Symposium, Sun Pharma, Takeda, Timber, Teladoc, Triveni, UCB, and Veradermics. |
Consultant | AbbVie, Almirall, Alumis, Amgen, Apogee, Arcutis, Botanix, Castle Biosciences, Connect BioPharma, Daiichi Sankyo, Dermavant, Disc Medicine, Eli Lilly, EPI Health/Novan, Galderma, Incyte, LEO Pharma, Novartis, Ortho Dermatologics, Palvella, Pfizer, Regeneron, Sanofi, South Beach Symposium, Sun Pharma, Takeda, Timber, Teladoc, Triveni, UCB, and Veradermics. | |
Researcher | AbbVie, Almirall, Apogee, Daiichi Sankyo, LEO Pharma, Ortho Dermatologics, Sun Pharma, Takeda, Timber, and Palvella | |
Jennifer L. Hsiao, MD | Consultant/Advisory board | AbbVie, Aclaris, Boehringer Ingelheim, Galderma, Incyte, Insmed, Moonlake, Leo Pharma, Navigator Medicines, Novartis, Oruka Therapeutics, Pfizer, Sanofi, Regeneron, UCB |
Researcher/Investigator | Amgen, AstraZeneca, Incyte, Novartis | |
Speaker | AbbVie, Galderma, Novartis, Sanofi, Regeneron, UCB | |
Dorothy Caputo, MA, BSN, RN, President | N/A | Nothing to disclose |
Rebecca Lakofsky, BSN, RN (planner/reviewer) | N/A | Nothing to disclose |
AKH Inc Staff and Planners | N/A | Nothing to disclose |
Tarsus dba LiVDerm Staff and Planners | N/A | Nothing to disclose |
All of the relevant financial relationships listed for these individuals have been mitigated. | ||
Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.
If you would like to opt out from future communications from AKH please send an email to [email protected] with your information with "Opt Out" in the subject line.
AKH Privacy Policy (link: https://akhcme.com/akhcme/pages/privacy )
Available Credit
- 0.75 AMA PRA Category 1 Credit™
- 0.75 Participation
Required Hardware/software
A computer with an internet connection
Other additional software may be required such as PowerPoint or Adobe Acrobat Reader.
PC Microsoft Internet Explorer 11 or later, Windows Edge browser, Mozilla Firefox, and Google Chrome For HTML Client – Google Chrome (v70.0 & above), Mozilla Firefox (v65.0 & above), and Edge (v42.0 & above)
| MAC Mozilla Firefox, Apple Safari, Google Chrome For HTML Client – Google Chrome (v70.0 & above), Apple Safari (v12.0 & above), and Mozilla Firefox (v65.0 & above)
|